COMPANY PROFILE

Xenothera

Explore full profile

Developing improved immunological treatments using their glyco-humanized antibody platform

Nantes, FranceFounded 2014Biotech & Life Sciences

Valuation $50–100M Last recorded · 2021

Revenue <$1M Latest reported FY

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Xenothera

Developer of immunosuppressants designed for transplantation and other indications. The company developed a Glyco-humanized antibody platform with embedded technology for the creation of hyperimmune polyclonal sera, enabling the medical community to optimize immunological treatments. Keywords: Pharmaceuticals and BiotechnologyDrug Develop Company, Drug Production, Drug Research, Genetic Engineering, Infectious Disease, Renal Transplantation.

Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: Nantes, France
Employees: 23
Open positions: None listed
Dealroom signal: 66.3/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Embedding Technology, Biotechnology, Oncology, DNA, Genetics and genomics, Immune System, Spinout, Genome Engineering, Sustainable Development Goals, EIC
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Funding history

10 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
LATE VC✓Equity / VC	Jun 2021	$22M	$88M	MH Innov' · Anaxago · EIC Fund	—
EARLY VC✓Equity / VC	Jun 2020	$3.1M	$12M	Undisclosed	—

Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue, earnings and profit over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

Year	Growth	Profit	Margin
2026
2025
2024
2023
2022
2021
2020	—	—	—

Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Xenothera website traffic

Latest recorded traffic for Xenothera is 960 monthly website visits, up 45.5% over the last three months. Xenothera's team declined 8% over the past year.

Latest monthly visits960 3-month web change+45.5% 1-year team growth-8%

Monthly website visitsFeb 2016–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
STStimunityTurn cancer immunotherapies active in most patient	Paris, France	Operational	2	$3.9M	$2.6M
CECellectisDeveloping allogeneic CAR-T cells	Paris, France	Operational
SPSparingVisionDeveloping an emerging therapy against the central vision loss generated by pigmentary retinopathies	Paris, France	Operational
HEHEPHAISTOS-PharmaDeveloping Tomorrow’s immuno-oncology and modulator therapy \| A single platform for defeating cancer and much more	Orsay, France	Operational
ELEpigene LabsHelping cancer researchers develop new treatments and drugs by providing them with data-driven insights	Paris, France	Operational
OSOsivaxA company developing "universal" vaccines able to prevent highly-mutating respiratory viral infections	Lyon, France	Operational
DEDepixusBringing the dynamic genome to life	Paris, France	Operational
DSDNA ScriptTransforming how molecular biology translates to human health, personalized medicine, and synthetic biology	Le Kremlin-Bicêtre, France	Operational